Adverse events · people with surgically‐induced remission in Crohn's disease
5‐ASAs showed no clear difference in adverse events compared with placebo (low certainty).
1 finding from 1 review
Adverse events · people with surgically‐induced remission in Crohn's disease
High dose 5‐ASA showed no clear difference in adverse events compared with low dose 5‐ASA (low certainty).
1 finding from 1 review
Adverse events · people with surgically‐induced remission in Crohn's disease
5‐ASA showed no clear difference in adverse events compared with purine antimetabolites (low certainty).
1 finding from 1 review
Adverse events · people with surgically‐induced remission in Crohn's disease
It is very uncertain whether 5‐ASAs changes adverse events compared with anti TNF‐ɑ (very low certainty).
1 finding from 1 review
Adverse events · people with surgically‐induced remission in Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · people with surgically‐induced remission in Crohn's disease
It is very uncertain whether 5‐ASA changes adverse events compared with no treatment (very low certainty).
1 finding from 1 review
RR 5 [0.25, 101.81]
110 participants
Very low
Adverse events · people with surgically‐induced remission in Crohn's disease
Azathioprine or 6‐mercaptopurine showed no clear difference in adverse events compared with 5‐aminosalicylic acid (low certainty).
1 finding from 1 review
Adverse events · people with surgically‐induced remission in Crohn's disease
Azathioprine or 6‐mercaptopurine showed no clear difference in adverse events compared with anti TNF‐α (low certainty).
1 finding from 1 review
Adverse events · people with surgically‐induced remission in Crohn's disease
Azathioprine or 6‐mercaptopurine showed no clear difference in adverse events compared with placebo (low certainty).
1 finding from 1 review
Adverse events · people with malignant gastric outlet obstruction
It is very uncertain whether duodenal stenting changes adverse events compared with surgical palliation (very low certainty).
1 finding from 1 review
Serious adverse events · people with surgically‐induced remission in Crohn's disease
5‐ASAs showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · people with surgically‐induced remission in Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people with surgically‐induced remission in Crohn's disease
It is very uncertain whether 5‐ASA changes serious adverse events compared with purine antimetabolites (very low certainty).
1 finding from 1 review
Serious adverse events · people with surgically‐induced remission in Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people with surgically‐induced remission in Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people with surgically‐induced remission in Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people with surgically‐induced remission in Crohn's disease
It is very uncertain whether azathioprine or 6‐mercaptopurine changes serious adverse events compared with 5‐aminosalicylic acid (very low certainty).
1 finding from 1 review
Serious adverse events · people with surgically‐induced remission in Crohn's disease
It is very uncertain whether azathioprine or 6‐mercaptopurine changes serious adverse events compared with anti TNF‐α (very low certainty).
1 finding from 1 review
Serious adverse events · people with surgically‐induced remission in Crohn's disease
Azathioprine or 6‐mercaptopurine showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with surgically‐induced remission in Crohn's disease
5‐ASAs showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).
1 finding from 1 review